Gold, R. Et Al. 2006. Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. 16th Annual Meeting of the European-Neurological-Society , (Lausanne, Switzerland), 144-145.

Gold, R., Havrdova, E., Kappos, L., Limmroth, V., Miller, D., Polman, C., ... Yang, M.(2006). Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study . 16th Annual Meeting of the European-Neurological-Society (pp.144-145). Lausanne, Switzerland

Gold, R. Et Al. "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study," 16th Annual Meeting of the European-Neurological-Society, Lausanne, Switzerland, 2006

Gold, R. Et Al. "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study." 16th Annual Meeting of the European-Neurological-Society , Lausanne, Switzerland, pp.144-145, 2006

Gold, R. Et Al. (2006) . "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study." 16th Annual Meeting of the European-Neurological-Society , Lausanne, Switzerland, pp.144-145.

@conferencepaper{conferencepaper, author={R. Gold Et Al. }, title={Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study}, congress name={16th Annual Meeting of the European-Neurological-Society}, city={Lausanne}, country={Switzerland}, year={2006}, pages={144-145} }